Scholarlink

Colorectal cancer is common and requires knowledge of RAS (KRAS/NRAS) status in order to decide on the possibility of anti-EGFR treatments (cetuximab, panitumumab). In our pathology laboratory at the Mohamed VI University Hospital in Oujda, we have implemented real-time PCR with TaqMan probes to detect these mutations on FFPE (Formalin-Fixed Paraffin-Embedded) blocks. Of 87 samples, 81 yielded usable DNA: 62 were wild-type RAS and 19 had a RAS mutation, mainly located at KRAS exon 12 (G12C/G12D/G12V), followed by a few KRAS Q61 mutations and rare cases of BRAF V600E. No significant isolated NRAS mutations were detected. The results were available quickly and provided optimal guidance for the indication of targeted therapies. The discussion showed that TaqMan PCR can be supplemented by: liquid biopsy (Digital Droplet PCR ddPCR) for non-invasive, quantitative ctDNA monitoring; high-throughput sequencing (NGS) for extensive molecular profiling; or epigenetic biomarkers for innovative diagnostics. The future lies in integrating these methods with artificial intelligence to deliver ever faster and more personalized precision oncology.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Experience of the Pathology Laboratory at Mohammed VI University Hospital of Oujda in the Molecular Analysis of Colorectal Cancers: A Retrospective Study of RAS Status Assessment by Real-Time PCR with TaqMan Probes

  • 会议论文

  • 发表日期：

    2026年

查看全文
  • Benheddi Maryam,
  • Haloui Anass,
  • Karich Nassira,
  • Bennani Amal

摘要

Colorectal cancer is common and requires knowledge of RAS (KRAS/NRAS) status in order to decide on the possibility of anti-EGFR treatments (cetuximab, panitumumab). In our pathology laboratory at the Mohamed VI University Hospital in Oujda, we have implemented real-time PCR with TaqMan probes to detect these mutations on FFPE (Formalin-Fixed Paraffin-Embedded) blocks. Of 87 samples, 81 yielded usable DNA: 62 were wild-type RAS and 19 had a RAS mutation, mainly located at KRAS exon 12 (G12C/G12D/G12V), followed by a few KRAS Q61 mutations and rare cases of BRAF V600E. No significant isolated NRAS mutations were detected. The results were available quickly and provided optimal guidance for the indication of targeted therapies. The discussion showed that TaqMan PCR can be supplemented by: liquid biopsy (Digital Droplet PCR ddPCR) for non-invasive, quantitative ctDNA monitoring; high-throughput sequencing (NGS) for extensive molecular profiling; or epigenetic biomarkers for innovative diagnostics. The future lies in integrating these methods with artificial intelligence to deliver ever faster and more personalized precision oncology.